Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...

Regeneron Pharmaceuticals announced initial results from the Phase 1b LINKER-MM2 trial evaluating linvoseltamab, used in combination with carfilzomib or bortezomib, for patients with relapsed ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC ...

Credit: NMK-Studio/Shutterstock. Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution for improving the management ...

Regeneron Pharmaceuticals acquiring genetic testing firm 23andMe for $256 million. The deal follows 23andMe’s Chapter 11 bankruptcy protection filing in March. Transaction excludes telehealth ...

It comes two months after 23andMe filed for Chapter 11 bankruptcy. Under the deal, Westchester County, New York-based Regeneron will take over 23andMe's personal genome service, total health, and ...